Interferon free hepatitis C treatment regimens: The beginning of another era

Current Gastroenterology Reports

Volumn 14, Issue 1, 2012, Pages 74-77

  Poordad, Fred ^a   Chee, Grace M ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Direct acting antivirals; Hepatitis C; Interferon; Interferon free; Polymerase inhibitor; Protease inhibitor; Ribavirin; SVR

Indexed keywords

ALPHA INTERFERON; ASUNAPREVIR; DACLATASVIR; DANOPREVIR; INTERFERON; MERICITABINE; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; PSI 7977; PSI 938; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANEMIA; ANTIVIRAL ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; PATIENT COMPLIANCE; SINGLE DRUG DOSE; STEADY STATE; VIRUS IMMUNITY;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS; INTERFERON-ALPHA; PROTEASE INHIBITORS; RIBAVIRIN; URIDINE MONOPHOSPHATE;

EID: 84857536087     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-011-0229-1     Document Type: Article

References (25)

1. QL Choo G Kuo AJ Weiner, et al. 1989 Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 21 244 359 362 10.1126/science.2523562 (Pubitemid 19117877)
2. T Poynard P Marcellin SS Lee, et al. 1998 Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 352 1426 332 9807989 10.1016/S0140-6736(98)07124-4 1:CAS:528:DyaK1cXnsVSmsLg%3D (Pubitemid 28510876)
3. JG McHutchinson SC Gordon ER Schiff, et al. 1998 Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C N Engl J Med 339 1485 1492 10.1056/NEJM199811193392101 (Pubitemid 28543496)
4. T Poynard P Marcellin SS Lee, et al. 1998 Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus Lancet 352 9138 1426 1432 9807989 10.1016/S0140-6736(98)07124-4 1:CAS:528:DyaK1cXnsVSmsLg%3D (Pubitemid 28510876)
5. P Glue JW Fang R Rouzier-Panis, et al. 2000 Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data Clin Pharmacol Ther 68 5 556 567 11103758 10.1067/mcp.2000.110973 1:CAS:528:DC%2BD3cXovVeru78%3D
6. M Grace S Youngster G Gitlin, et al. 2001 Structural and biologic characterization of pegylated recombinant IFN-alpha2b J Interferon Cytokine Res 21 12 1103 1115 11798469 10.1089/107999001317205240 1:CAS:528: DC%2BD38XlsVyqtw%3D%3D (Pubitemid 34121056)
7. P Bailon A Palleroni CA Schaffer, et al. 2001 Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon a-2a for the treatment of hepatitis C Bioconjug Chem 12 2 195 202 11312680 10.1021/bc000082g 1:CAS:528:DC%2BD3MXhtFGlur8%3D (Pubitemid 32235471)
8. MP Manns JG McHutchison SC Gordon, et al. 2001 Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 9286 958 965 11583749 10.1016/S0140-6736(01)06102-5 1:CAS:528:DC%2BD3MXntF2qtb8%3D (Pubitemid 32913521)
9. MW Fried ML Shiffman KR Reddy, et al. 2002 Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 13 975 982 12324553 10.1056/NEJMoa020047 1:CAS:528:DC%2BD38Xnt12rtb0%3D
10. JG McHutchison EJ Lawitz ML Shiffman, et al. 2009 Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Eng J Med 361 580 593 10.1056/NEJMoa0808010 1:CAS:528:DC%2BD1MXps1Kjuro%3D
11. S Flamm E Lawitz I Jacobson, et al. 2011 High Sustained Virologic Response (SVR) among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir (BOC) plus peginterferon alfa-2A/ribavirin J Hepatol 54 A1366 10.1016/S0168-8278(11)61368-8
12. BR Bacon SC Gordon E Lawitz, et al. 2011 Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med. 364 1207 1217 21449784 10.1056/NEJMoa1009482 1:CAS:528:DC%2BC3MXkt1Cht7k%3D
13. Poordad F, Chee GM: Pharmacology and mechanisms of action of antiviral drugs: Ribavirin analogues. Advanced Therapy for Hepatitis C Infection. 2011, Wiley-Blackwell (In press)
14. MW Fried ML Shiffman KR Reddy, et al. 2002 Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975 982 12324553 10.1056/NEJMoa020047 1:CAS:528:DC%2BD38Xnt12rtb0%3D
15. F Poordad J McCone Jr BR Bacon, et al. 2011 Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med. 364 1195 1206 21449783 10.1056/NEJMoa1010494 1:CAS:528:DC%2BC3MXkt1Chtrc%3D
16. IM Jacobson JG McHutchison G Dusheiko, et al. 2011 Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med. 364 2405 2416 21696307 10.1056/NEJMoa1012912 1:CAS:528:DC%2BC3MXotVCku7Y%3D
17. M Gale MG Katze 1998 Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon induced protein kinase Pharmacol. Ther. 78 29 46 9593328 10.1016/S0163-7258(97)00165-4 1:CAS:528:DyaK1cXitleksrc%3D (Pubitemid 28178928)
18. D Ge J Fellay AJ Thompson, et al. 2009 Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature. 461 399 401 19684573 10.1038/nature08309 1:CAS:528:DC%2BD1MXpvFCrtbw%3D
19. AJ Thompson AJ Muir MS Sulkowski, et al. 2010 IL28B Polymorphism Improves Viral Kinetics and Is the Strongest Pre-treatment Predictor of SVR in HCV-1 Patients Gastroenterology 139 120 129 20399780 10.1053/j.gastro.2010.04.013 1:CAS:528:DC%2BC3cXpsFait7s%3D A key paper describing the clinical effects of the IL28B polymorphism on response rates in HCV genotype 1 patients
20. Poordad F, Bronowicki J-P, Gordon SC, et al.: IL28B Polymorphism Predicts Virologic Response in Patients With Hepatitis C Genotype 1 Treated With Boceprevir (Boc) Combination Therapy. Gastroenterology 2011;A1864
21. S Zeuzem P Andreone S Pol, et al. 2011 REALIZE study team: telaprevir for retreatment of HCV infection N Engl J Med. 364 25 2417 2428 21696308 10.1056/NEJMoa1013086 1:CAS:528:DC%2BC3MXotVCrsrg%3D
22. EJ Gane SK Roberts CA Stedman, et al. 2010 Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 376 1467 1475 20951424 10.1016/S0140-6736(10)61384-0 1:CAS:528:DC%2BC3cXhtlKjs7nF The first study assessing two compounds with different mechanisms of action targeting HCV and showing good antiviral effects. This ultimately allowed for the discussion of interferon free regimens
23. A Lok D Gardiner E Lawitz, et al. 2011 Quadruple therapy with MBS-790052, BMS-650032 and peginterferon/ribavirin for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders J Hepatol 54 suppl S536 10.1016/S0168-8278(11) 61358-5 An important study, and the first to show that null patients can be cured of HCV using only 2 oral agents for 24 weeks. This presentation changed many perspectives about the possibilities of what interferon free regimens can do
24. J Lalezari E Lawitz M Rodriguez-Torres, et al. 2011 PSI-7977 QD with Peg/RBV: 12-week Safety, RVR, cEVR, and SVR12 in treatment-naïve patients with HCV GT2 or GT3 J of Hepatology 54 A61
25. E Lawitz M Rodriguez-Torres J Denning, et al. 2011 Once daily dual-nucleotide combination of PSI-928 and PSI-7977 provides 95% HCV RNA